Insulin lispro update

被引:8
作者
Meece, JD [1 ]
Campbell, RK [1 ]
机构
[1] Plaza Pharm & Wellness Ctr, Clin Serv, Gainesville, FL USA
关键词
D O I
10.1177/014572170202800212
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE This paper provides a review of the literature and clinical studies for insulin lispro and updated information on its advantages over regular insulin 11 for various populations of people with diabetes. METHODS Information was gathered from a search of Medline articles and from review of clinical studies. RESULTS Patients in various special populations using insulin lispro, with proper adjustment of basal insulin, bad a greater reduction in hemoglobin A 1 C and fewer episodes of hypoglycemia than patients on regular insulin. CONCLUSIONS More recently published literature shows that due to its faster onset and shorter duration of action, insulin lispro is useful for not only lowering A 1 C values, but also for reducing hypoglycemic events in various populations with diabetes, including pediatric and pregnant patients, those with gastroparesis, and insulin pump users.
引用
收藏
页码:269 / 277
页数:9
相关论文
共 18 条
[1]   Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment [J].
Anderson, JH ;
Brunelle, RL ;
Koivisto, VA ;
Pfutzner, A ;
Trautmann, ME ;
Vignati, L ;
DiMarchi, R ;
Bowen, KM ;
Cameron, DP ;
Nankervis, AJ ;
Roberts, AP ;
Zimmet, P ;
Borkenstein, MH ;
Schernthaner, G ;
Waldhausl, WK ;
DeLeeuw, IH ;
Fery, F ;
Scheen, A ;
Somers, G ;
Fettes, IM ;
Tildesley, HD ;
Toth, EL ;
Viikari, J ;
Altman, JJ ;
Bougneres, PF ;
Drouin, P ;
Fossati, P ;
Guillausseau, PJ ;
Marechaud, E ;
Riou, JP ;
Selam, JL ;
Vialettes, PB ;
Beyer, J ;
Federlin, K ;
Fussganger, RD ;
Gries, FA ;
Jastram, HU ;
Koop, I ;
Landgraf, R ;
Rosak, C ;
Schatz, H ;
SchulzeSchleppinghoff, B ;
Seif, FJ ;
Stoeckmann, F ;
Karasik, A ;
Weitzman, S ;
Andreani, D ;
Bompiani, G ;
Crepaldi, G ;
Giorgino, R .
DIABETES, 1997, 46 (02) :265-270
[2]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[3]  
CAMPBELL RK, 2000, US PHARM, V23, P12
[4]   Strategies toward improved control during insulin lispro therapy in IDDM - Importance of basal insulin [J].
Ebeling, P ;
Jansson, PA ;
Smith, U ;
Lalli, C ;
Bolli, GB ;
Koivisto, VA .
DIABETES CARE, 1997, 20 (08) :1287-1289
[5]  
*EL LILL CO, 1999, DAT FIL
[6]  
FULLER JH, 1980, LANCET, V1, P1373
[7]  
Garg SK, 1999, DIABETES, V48, pA61
[8]   Risk factors for myocardial infarction and death in newly detected NIDDM: The diabetes intervention study, 11-year follow-up [J].
Hanefeld, M ;
Fischer, S ;
Julius, U ;
Schulze, J ;
Schwanebeck, U ;
Schmechel, H ;
Ziegelasch, HJ ;
Lindner, J .
DIABETOLOGIA, 1996, 39 (12) :1577-1583
[9]  
HELLER SR, 1997, DIABETES S1, V46, pA151
[10]   [LYS(B28), PRO(B29)]-HUMAN INSULIN - A RAPIDLY ABSORBED ANALOG OF HUMAN INSULIN [J].
HOWEY, DC ;
BOWSHER, RR ;
BRUNELLE, RL ;
WOODWORTH, JR .
DIABETES, 1994, 43 (03) :396-402